Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Income from Continuing Operations (2021 - 2025)

Historic Income from Continuing Operations for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to -$52.8 million.

  • Prime Medicine's Income from Continuing Operations fell 59.79% to -$52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$199.6 million, marking a year-over-year increase of 896.7%. This contributed to the annual value of -$195.9 million for FY2024, which is 113.61% up from last year.
  • Prime Medicine's Income from Continuing Operations amounted to -$52.8 million in Q3 2025, which was down 59.79% from -$52.6 million recorded in Q2 2025.
  • Prime Medicine's Income from Continuing Operations' 5-year high stood at -$16.4 million during Q3 2021, with a 5-year trough of -$65.6 million in Q4 2023.
  • Moreover, its 5-year median value for Income from Continuing Operations was -$45.8 million (2024), whereas its average is -$44.3 million.
  • Within the past 5 years, the most significant YoY rise in Prime Medicine's Income from Continuing Operations was 3754.39% (2022), while the steepest drop was 7883.26% (2022).
  • Quarter analysis of 5 years shows Prime Medicine's Income from Continuing Operations stood at -$62.9 million in 2021, then soared by 37.54% to -$39.3 million in 2022, then crashed by 67.1% to -$65.6 million in 2023, then surged by 35.6% to -$42.3 million in 2024, then fell by 24.97% to -$52.8 million in 2025.
  • Its last three reported values are -$52.8 million in Q3 2025, -$52.6 million for Q2 2025, and -$51.9 million during Q1 2025.